<DOC>
	<DOCNO>NCT02407899</DOCNO>
	<brief_summary>The main purpose study evaluate whether saxagliptin ( vitamin D3 ) insulin therapy well protect islet β cell function insulin alone .</brief_summary>
	<brief_title>Protective Effects Saxagliptin ( And Vitamin D3 ) β Cell Function Patients With Adult-onset Latent Autoimmune Diabetes</brief_title>
	<detailed_description>LADA actually form type 1 diabetes , cause autoimmune damage islet β cell trigger environmental factor base genetic susceptibility . LADA show characteristic type 2 diabetes onset , develop slowly latently , easily misdiagnosed type 2 diabetes due slowly β cell function deterioration . This multi-center , open-label , 1:1:1 randomize control trial investigate protective efficacy saxagliptin vitamin D3 LADA patient previously treat insulin . The study comprise twice screening , 8-week run-in period 104-week treatment period . The first screening choose LADA patient diabetes patient whose disease duration &lt; 1 year . After obtain informed consent patient willing participate 104-week treatment enter 8-week run-in period receive guidance diet , exercise , insulin , blood glucose monitoring , patient diary recording , etc . The second screening find eligible patient 6-week 8-week run-in period accord inclusion/exclusion criterion , patient randomize 104-week treatment period . Subjects randomize three group central dynamic randomization : insulin , insulin+saxagliptin , insulin+saxagliptin+vitamin D3 . Our previous randomized-controlled pilot study show dipeptidyl peptidase 4 ( DPP-4 ) inhibitor could significantly improve islet β-cell function patient LADA . The main purpose study : evaluate whether saxagliptin ( vitamin D3 ) insulin therapy well protect islet β cell function insulin alone .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
	<criteria>1 . Volunteer participate study informed consent ; 2 . Meet Chinese Diabetes Society diagnostic criterion ( 2012 ) LADA : ( 1 ) glutamic acid decarboxylase antibody ( GADA ) positive ; ( 2 ) age diagnosis ≧ 18 year old ; ( 3 ) independent insulin 6 month diagnosis ; 3 . Age 1870 year old ; 4 . Diabetes duration ≦ 1 year ; 5 . HbA1c ≦ 7.5 % ; 6 . Daily required insulin ≦ 0.8 IU/kg ; 7 . Serum fast Cpeptide &gt; 200 pmol/L 2hour postprandial Cpeptide &gt; 400 pmol/L ; 1 . Pregnancy , breastfeed plan pregnancy within two year ; 2 . Gestational diabetes mellitus specific type diabetes ; 3 . Allergic saxagliptin , vitamin D3 excipient ; 4 . Treatment antidiabetic medication insulin last 8 week prior randomization ; 5 . Use systemic corticosteroid therapy ( oral , intravenous ) continuously 7 day past 6 month ; 6 . Treatment cytochrome P450 3A4/5 ( CYP450 3A4/5 ) inhibitor ; 7 . Alanine aminotransferase ( ALT ) aspartate transaminase ( AST ) 3 time normal upper limit , total bilirubin ( TBIL ) 2 time normal upper limit ; 8 . Creatinine level ≧ 1.5 mg/dL ( 132μmol/L ) male ≧ 1.4 mg/dL ( 123μmol/L ) female creatinine clearance ≦ 50 mL/min ; 9 . History malignant tumor ; 10 . History mental disorder ; 11 . History alcohol abuse illegal drug abuse ; 12 . Serious systemic disease investigator think would suitable study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>LADA</keyword>
	<keyword>saxagliptin</keyword>
	<keyword>vitamin D3</keyword>
	<keyword>C-Peptide</keyword>
</DOC>